New drug cocktail aims to tackle tough lung cancers

NCT ID NCT07472647

Not yet recruiting Disease control Sponsor: Shanghai JMT-Bio Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase study tests a new drug called SYS6090 combined with standard chemotherapy or other drugs in about 600 people with advanced lung cancer (non-small cell or small cell). The goal is to see if the combinations are safe and if they can shrink tumors. The trial is not yet recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SYS6090 (a drug) given with chemotherapy (pemetrexed, paclitaxel, docetaxel, platinum-based drugs) or with bevacizumab or another drug called SYS6010
What this could lead to: If it works, this could point toward a new combination treatment that shrinks tumors or slows lung cancer growth.
What could go wrong: This is an early-phase trial (phase 1b/2) that hasn't started recruiting yet. It primarily checks safety and dosing, so it's too soon to know if it will help patients. Side effects from combining multiple drugs are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER SMALL CELL LUNG CANCER

More trials for these conditions

Other studies related to the condition(s) this trial covers.